# ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)

Source: https://onco.cc/terms/abvd-beacopp/  
OnCo record `abvd-beacopp` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The chemotherapy recipes that cure most Hodgkin lymphoma: ABVD (four drugs, the long-standing standard), the more intensive German BEACOPP, and newer versions that replace bleomycin with brentuximab vedotin (A+AVD) or add nivolumab (N-AVD).

## Summary

ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) cures 70-80% of advanced disease with interim PET guiding bleomycin omission (RATHL); escalated BEACOPP raises progression-free survival to about 90% at the cost of infertility and secondary cancers. A+AVD improved survival over ABVD (ECHELON-1), N-AVD beat A+AVD on progression-free survival in SWOG S1826 (2024), and BrECADD matched escalated BEACOPP with less toxicity (HD21). Late effects of these curative regimens (cardiac, pulmonary, breast cancer after radiotherapy) drive the continuing effort to de-escalate.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: ABVD; A+AVD; AVD; BV-AVD; brentuximab vedotin-AVD; BEACOPP; escalated BEACOPP; eBEACOPP; BrECADD; N-AVD; nivolumab-AVD; Stanford V

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/ABVD
- Wikipedia: https://en.wikipedia.org/wiki/ABVD

## Connected records

- terms: [De-escalation, escalation and response-adapted therapy](https://onco.cc/terms/de-escalation/), [Deauville score and PET-adapted therapy](https://onco.cc/terms/deauville/), [Fertility before lymphoma treatment: what to ask for, and when](https://onco.cc/terms/lymphoma-tx-fertility-preservation/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Secondary malignancy (therapy-related cancer)](https://onco.cc/terms/secondary-malignancy/), [The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest](https://onco.cc/terms/lymphoma-tx-regimen-alphabet/)
- cancers: [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Early-stage classical Hodgkin lymphoma (stage I to II)](https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)](https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- drugs: [Bleomycin](https://onco.cc/drugs/bleomycin/), [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Vinblastine](https://onco.cc/drugs/vinblastine/)
- trials: [AHL2011](https://onco.cc/trials/ahl2011/), [EORTC/LYSA/FIL H10](https://onco.cc/trials/eortc-h10/), [GHSG HD10](https://onco.cc/trials/hd10/), [GHSG HD16](https://onco.cc/trials/hd16/), [GHSG HD18](https://onco.cc/trials/hd18/), [RADAR](https://onco.cc/trials/radar-hodgkin/)
- key papers: [Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial](https://onco.cc/key-papers/paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017/), [PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study](https://onco.cc/key-papers/paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019/), [PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group](https://onco.cc/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/), [Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group](https://onco.cc/key-papers/paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)
- ideas: [A radiotherapy-free cure for early Hodgkin lymphoma that actually holds](https://onco.cc/ideas/lymphoma-ev-radiotherapy-free-early-hodgkin/)

---
JSON: https://onco.cc/api/v1/entities/abvd-beacopp.json